<DOC>
	<DOCNO>NCT00761735</DOCNO>
	<brief_summary>Study P02538 Part 2 5-year long term follow-up ( LTFU ) study pediatric participant treat least one dose peginterferon alfa-2b ( PEG-IFN ) ribavirin ( RBV ) complete follow-up P02538 Part 1 study ( NCT00104052 ) . No study drug therapy administer P02538 Part 2 study . Durability virologic response assess participant attain sustained virologic response ( SVR ) Part I study perform annual Hepatitis C Virus ribonucleic acid ( HCV-RNA ) test . In addition , study characterize long-term safety participant receive PEG-IFN plus RBV treatment .</brief_summary>
	<brief_title>5 Year Long-term Follow Pediatric Participants Who Received PegIntron Plus Rebetol P02538 Part I ( P02538 Pt 2 )</brief_title>
	<detailed_description>During Part 2 LTFU , participant evaluate Years 1 , 2 , 3 , 4 , 5 . Each participant 's first LTFU visit schedule approximately 1 year post-treatment Follow-up Week 24 visit Part 1 study ( NCT00104052 ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Informed consent must obtain participant participant 's parent legal guardian prior longterm followup studyrelated procedure . According local law and/or IRB/IEC requirement , participant may also need provide write assent . The participant must receive least one dose peginterferon alfa2b ribavirin Protocol No . P02538 study . The participant must complete 24week posttreatment followup P02538 Part 1 study . All participant whether sustained responder , relapsers , nonresponders eligible participate . Concurrent participation clinical study . Retreatment antiviral immunomodulatory drug chronic hepatitis C completion , discontinuation , treatment phase P02538 Part 1 study . Any condition opinion Investigator would make participant unsuitable enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>